Literature DB >> 20087318

Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy.

Yu-Qian Zhang1, Ya-Chea Tsai, Archana Monie, T-C Wu, Chien-Fu Hung.   

Abstract

Cancer therapy using oncolytic viruses represents a promising new approach for controlling ovarian cancer. In this study, we have circumvented the limitation of repeated vaccination by employing different virus vectors, Semliki Forest Virus (SFV) and vaccinia virus (VV) for boosting the immune response. We found that infection of tumor-bearing mice with VV followed by infection with SFV or vice versa leads to enhanced antitumor effects against murine ovarian surface epithelial carcinoma (MOSEC) tumors. Furthermore, infection with VV-ovalbumin (OVA) followed by infection with SFV-OVA or vice versa was found to lead to enhanced OVA-specific CD8(+) T-cell immune responses. In addition, we found that infection with SFV-OVA followed by infection with VV-OVA leads to enhanced antitumor effects in vivo and enhanced tumor killing in vitro through a combination of viral oncolysis and antigen-specific immunity. The clinical implications of this study are discussed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20087318      PMCID： PMC2862517          DOI： 10.1038/mt.2009.318

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


  23 in total

1.  Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.

Authors:  Jan Wierecky; Martin R Müller; Stefan Wirths; Edith Halder-Oehler; Daniela Dörfel; Susanne M Schmidt; Maik Häntschel; Wolfram Brugger; Stephen Schröder; Marius S Horger; Lothar Kanz; Peter Brossart
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

2.  In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.

Authors:  Hiroyoshi Nishikawa; Eiichi Sato; Gabriel Briones; Li-Mei Chen; Mitsutoshi Matsuo; Yasuhiro Nagata; Gerd Ritter; Elke Jäger; Hideki Nomura; Shigeto Kondo; Isao Tawara; Takuma Kato; Hiroshi Shiku; Lloyd J Old; Jorge E Galán; Sacha Gnjatic
Journal:  J Clin Invest       Date:  2006-06-22       Impact factor: 14.808

3.  Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice.

Authors:  C-F Hung; Y-C Tsai; L He; G Coukos; I Fodor; L Qin; H Levitsky; T-C Wu
Journal:  Gene Ther       Date:  2006-08-17       Impact factor: 5.250

4.  Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain.

Authors:  Youichi Unno; Yuji Shino; Fukuo Kondo; Natsuhiko Igarashi; Gang Wang; Ryuhi Shimura; Taketo Yamaguchi; Takehide Asano; Hiromitsu Saisho; Souei Sekiya; Hiroshi Shirasawa
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

5.  Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses.

Authors:  K Ikeda; T Ichikawa; H Wakimoto; J S Silver; T S Deisboeck; D Finkelstein; G R Harsh; D N Louis; R T Bartus; F H Hochberg; E A Chiocca
Journal:  Nat Med       Date:  1999-08       Impact factor: 53.440

6.  Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor.

Authors:  Shari A Pilon; Carmen Kelly; Wei-Zen Wei
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

7.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.

Authors:  Pilar Nava-Parada; Guido Forni; Keith L Knutson; Larry R Pease; Esteban Celis
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models.

Authors:  Jen-Chieh Tseng; Alicia Hurtado; Herman Yee; Brandi Levin; Christopher Boivin; Marta Benet; Stephanie V Blank; Angel Pellicer; Daniel Meruelo
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

Review 9.  Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.

Authors:  H Wakimoto; P R Johnson; D M Knipe; E A Chiocca
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

10.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702
View more
  28 in total

1.  Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Authors:  Di Yu; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Fredrik Eriksson; Magnus Essand
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

Review 2.  Thunder and lightning: immunotherapy and oncolytic viruses collide.

Authors:  Alan Melcher; Kelley Parato; Cliona M Rooney; John C Bell
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

3.  Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.

Authors:  Diana L Thomas; Rosalinda Doty; Vesna Tosic; Jia Liu; David M Kranz; Grant McFadden; Amy L Macneill; Edward J Roy
Journal:  Cancer Immunol Immunother       Date:  2011-06-09       Impact factor: 6.968

4.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

5.  Orf Virus-Based Therapeutic Vaccine for Treatment of Papillomavirus-Induced Tumors.

Authors:  M Schneider; M Müller; A Yigitliler; J Xi; C Simon; T Feger; H-J Rziha; F Stubenrauch; H-G Rammensee; T Iftner; R Amann
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

6.  Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.

Authors:  Phonphimon Wongthida; Rosa Maria Diaz; Christine Pulido; Diana Rommelfanger; Feorillo Galivo; Karen Kaluza; Timothy Kottke; Jill Thompson; Alan Melcher; Richard Vile
Journal:  Hum Gene Ther       Date:  2011-04-11       Impact factor: 5.695

7.  Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy.

Authors:  Paul T Sobol; Jeanette E Boudreau; Kyle Stephenson; Yonghong Wan; Brian D Lichty; Karen L Mossman
Journal:  Mol Ther       Date:  2010-11-30       Impact factor: 11.454

8.  Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma.

Authors:  Markus J V Vähä-Koskela; Fabrice Le Boeuf; Chantal Lemay; Naomi De Silva; Jean-Simon Diallo; Julie Cox; Michelle Becker; Youngmin Choi; Abhirami Ananth; Clara Sellers; Sophie Breton; Dominic Roy; Theresa Falls; Jan Brun; Akseli Hemminki; Ari Hinkkanen; John C Bell
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

9.  Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors.

Authors:  Daejin Kim; Talia Hoory; Archana Monie; Annie Wu; Wei-Ting Hsueh; Sara I Pai; Chien-Fu Hung
Journal:  J Biomed Sci       Date:  2010-07-26       Impact factor: 8.410

10.  Antitumor effects and mechanisms of dendritic cells stimulated by sCD40L on ovarian cancer cells in vitro.

Authors:  Zheng-Mao Zhang; Xue-Mei Yang; Chao Zhang; Min-Jie Zhang; Xia Li; Feng-Hua Zhang; Shan Kang; Shi-Jie Wang; Bao-En Shan
Journal:  Onco Targets Ther       Date:  2013-05-06       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.